Generics· August 27, 2026 · 17 min read
FDA's Cabazitaxel 314.161 Notice: ANDAs to Dead 10 mg/mL NDA, Not Jevtana Kit
By Ran Chen#Generics#Orange Book#505(b)(2)
Topic
505(b)(2)
Hybrid applications, reliance strategy, bridging data, and commercial use cases between full NDA and ANDA.
Generics· August 25, 2026 · 18 min read
Dasynoc's CRL Is a Facility Letter: Nine AB Generics and Phyrago Occupy Access
By Ran Chen#Generics#505(b)(2)#Orange Book
Generics· August 23, 2026 · 17 min read
FDA's August 2026 TE Final: 505(b)(2) Requests and Orange Book Blanks
By Ran Chen#Orange Book#505(b)(2)#FDA Approval
Generics· June 25, 2026 · 19 min read
Generic Forteo: Drug-Device Pathways and PBM Exclusions
By Ran Chen#Generics#Orange Book#505(b)(2)
Approvals· June 8, 2026 · 9 min read
FDA drug-device combination product pathway: PMOA and launch strategy
Generics· May 6, 2026 · 3 min read
Generic entry, ANDA, and 505(b)(2): the commercial difference
By Ran Chen#Generics#505(b)(2)#Orange Book